Arcangelisia flava

Arcangelisia flava contains isoquinoline alkaloids—principally berberine, palmatine, and fibraurin—that exert antimicrobial, antifungal, and antioxidant effects through enzyme inhibition and molecular target binding. In vitro xanthine oxidase inhibition by the ethanol stem extract yielded an IC50 of 30.44 ppm, approaching that of the reference drug allopurinol at 24.03 ppm, though no human clinical trials have yet confirmed these effects.

Origin & History

Arcangelisia flava is a woody liana belonging to the family Menispermaceae, native to the tropical rainforests of Southeast Asia, including Indonesia, Vietnam, Malaysia, the Philippines, and Thailand. It typically grows in humid lowland and montane forest understories, climbing host trees in regions with high rainfall and rich, well-drained soils. The plant is harvested predominantly from wild populations, with stems and roots serving as the primary medicinal plant parts used in traditional practice.

Historical & Cultural Context

Arcangelisia flava has a documented history of use across multiple Southeast Asian traditional medicine systems, including Jamu (Indonesian traditional medicine) and Vietnamese folk herbalism, where the stems and roots are administered as decoctions for the treatment of malaria, intermittent fevers, jaundice, and gastrointestinal disorders including diarrhea. In Indonesian practice, the plant is colloquially referenced by names reflecting its yellow-colored wood and stems, a visual property attributable to the high berberine content that imparts a characteristic golden hue. The plant has also been used in the Philippines and Malaysia for bitter tonic preparations, paralleling the use of other berberine-rich plants in Ayurvedic and Chinese medicine. Its inclusion in regional pharmacopeias and ethnobotanical surveys underscores its cultural significance as a multi-purpose medicinal liana in tropical Asia, though formal documentation in historical medical texts remains sparse compared to more widely studied Menispermaceae relatives.

Health Benefits

- **Antimalarial Activity**: Berberine and palmatine have demonstrated binding affinity toward Plasmodium falciparum telomerase in silico, supporting the traditional use of Arcangelisia flava in Vietnamese and Indonesian medicine for the treatment of malarial fevers.
- **Antifungal Effects**: Molecular docking studies show palmatine and fibraurin bind the fungal enzyme lanosterol 14α-demethylase (3LD6) with binding energies of −6.6377 kcal/mol and −6.7075 kcal/mol respectively, forming hydrogen bonds with residues Phe234, Arg448, Tyr131, and Ile450 to inhibit Candida species growth.
- **Antibacterial Properties**: Berberine has demonstrated in vitro binding to bacterial targets 1UAG in Escherichia coli and 7RM7 in Staphylococcus aureus, suggesting a mechanism for the plant's traditional use in treating diarrhea and infectious ailments.
- **Xanthine Oxidase Inhibition and Antigout Potential**: The ethanol stem extract inhibits xanthine oxidase with an IC50 of 30.44 ppm, significantly more potent than the leaf extract (174.62 ppm), indicating potential utility in reducing uric acid production relevant to gout management.
- **Antioxidant Activity**: Flavonoids including luteolin, quercetin, and isorhamnetin, together with the phenolic piceatannol present in the plant, contribute to free radical scavenging and reduction of oxidative stress, with stems showing superior antioxidant activity to leaves in vitro.
- **Antidiabetic Potential**: Berberine, a well-characterized alkaloid in the plant, is associated with AMPK pathway activation and inhibition of glucose production enzymes, though Arcangelisia flava-specific antidiabetic data remain at the preclinical stage.
- **Anti-inflammatory and Antipyretic Use**: Traditional Vietnamese and Indonesian applications for fever and jaundice align with the anti-inflammatory properties of berberine and palmatine, which modulate inflammatory signaling pathways, though formal mechanism studies specific to this species are limited.

How It Works

The primary alkaloids berberine and palmatine act through multi-target inhibition: berberine intercalates with bacterial DNA gyrase and topoisomerase IV, while both compounds inhibit xanthine oxidase, reducing uric acid synthesis at the enzymatic level. Palmatine and fibraurin competitively bind the fungal cytochrome P450 enzyme lanosterol 14α-demethylase, disrupting ergosterol biosynthesis in the fungal cell membrane with binding free energies around −6.6 to −6.7 kcal/mol, as revealed by in silico molecular docking against the 3LD6 crystal structure. Flavonoids such as luteolin and quercetin inhibit reactive oxygen species generation through metal chelation and direct radical scavenging, while berberine's activation of AMP-activated protein kinase (AMPK) contributes to glucose metabolism modulation observed in related species. Antimalarial effects are hypothesized to involve interference with Plasmodium falciparum telomerase function based on computational binding studies, though biochemical validation in parasite cultures remains incomplete.

Scientific Research

Research on Arcangelisia flava is restricted entirely to in vitro bioassays, phytochemical profiling, and in silico molecular docking studies; no registered human clinical trials or controlled animal efficacy studies have been published as of the available literature. Phytochemical investigations have identified the alkaloid, flavonoid, furanoditerpene, and tannin constituents from methanol, ethanol, and dichloromethane extracts, with one study quantifying total flavonoids in the methanol stem extract at 16.7 ppm. Antimicrobial minimum inhibitory concentration (MIC) assays and xanthine oxidase inhibition studies provide quantitative in vitro data, such as the stem extract IC50 of 30.44 ppm for xanthine oxidase versus allopurinol's 24.03 ppm. The overall evidence base is preliminary, with no pharmacokinetic, bioavailability, or toxicology studies in mammals, and findings cannot yet be extrapolated to therapeutic recommendations in humans.

Clinical Summary

There are no published human clinical trials evaluating the safety or efficacy of Arcangelisia flava or its standardized extracts for any health indication. The entirety of available efficacy data derives from in vitro enzyme inhibition assays, antimicrobial disk-diffusion or broth dilution studies, and computational molecular docking analyses. While in vitro xanthine oxidase inhibition (IC50 30.44 ppm for stem ethanol extract) and antifungal docking results are promising, these outcomes have not been validated in animal models or humans, making effect size estimation and clinical confidence impossible at this stage. Researchers have noted that clinical feasibility studies and toxicological assessments are prerequisite before any human application can be considered.

Nutritional Profile

Arcangelisia flava is not consumed as a food source and does not carry significant macronutrient or micronutrient value; its relevance is entirely phytochemical. The principal bioactive phytochemicals are isoquinoline alkaloids—berberine, palmatine, and fibraurin—present in the stems and roots, with berberine typically the dominant alkaloid in Menispermaceae species, though species-specific quantitative alkaloid concentrations for Arcangelisia flava have not been published. Flavonoids including luteolin, quercetin, isorhamnetin, and the stilbenoid piceatannol have been detected, with total flavonoid content in the methanol stem extract measured at 16.7 ppm in one study; tannins and furanoditerpenes are also present but unquantified. Bioavailability of berberine-class alkaloids is generally low due to P-glycoprotein efflux and first-pass hepatic metabolism, a factor relevant to any future formulation development for this plant.

Preparation & Dosage

- **Traditional Decoction (Stem/Root)**: Stems and roots are boiled in water to prepare aqueous decoctions used in Vietnamese and Indonesian folk medicine for fever and malaria; no standardized volume or concentration is established.
- **Ethanol Extract (Laboratory Standard)**: Used in research settings at concentrations typically between 10–200 ppm for in vitro bioassays; not commercially available as a standardized supplement.
- **Methanol Extract**: Employed for phytochemical isolation and compound quantification (e.g., 16.7 ppm total flavonoids in stem); not suitable for human consumption directly.
- **Dichloromethane Extract**: Used in antifungal and antimicrobial isolation studies; laboratory use only.
- **Supplemental Dose**: No clinically validated or commercially standardized supplemental dose exists for any form of Arcangelisia flava; no capsule, tablet, or tincture standardization has been published.
- **Timing Notes**: Traditional preparations are typically administered during febrile illness episodes; no pharmacokinetic data inform timing recommendations.

Synergy & Pairings

Berberine-containing plants like Arcangelisia flava are hypothesized to show synergy with quercetin, one of the plant's own flavonoid constituents, as quercetin inhibits P-glycoprotein-mediated efflux of berberine, potentially increasing intracellular berberine concentrations and bioavailability in a self-synergistic whole-extract effect. In the broader berberine literature, co-administration with silymarin or piperine has been shown to enhance oral bioavailability by up to 30–60%, suggesting that similar formulation strategies could apply to Arcangelisia flava stem extracts if developed. For antimalarial applications, combination with artemisinins or other plant-derived antimalarials such as Andrographis paniculata is speculative but mechanistically plausible given complementary target profiles across the parasite life cycle.

Safety & Interactions

Formal safety evaluation of Arcangelisia flava in humans or standardized animal toxicology studies has not been published, and the safety profile must be considered unknown beyond preliminary signals. Cytotoxic activity has been observed in brine shrimp lethality assays for plant extracts, indicating bioactive potency that warrants caution, and no maximum safe dose or no-observed-adverse-effect level (NOAEL) has been established. Berberine, the principal alkaloid constituent, is known in other contexts to inhibit CYP3A4 and P-glycoprotein, creating potential interactions with drugs metabolized by these pathways including cyclosporine, statins, and certain antiretrovirals, and these interactions should be extrapolated as a precautionary concern. Use during pregnancy and lactation is contraindicated on a precautionary basis given berberine's documented uterotonic properties and potential fetal toxicity observed in berberine-containing plant studies.